MAP2K7 and melanoma: For BRAF mutation-positive patients with melanoma, BRAF inhibitors such as vemurafenib or dabrafenib were regarded as the standard therapy, but in a short time the combination of BRAF inhibitor and MEK inhibitor became the standard therapy.